claimgotdeniedAnalyze

Remicade (infliximab) and biosimilars prior authorization denied appeal

TNF inhibitor (IV infusion) for RA, PsA, AS, PsO, Crohn's, UC

To appeal a denied prior authorization for Remicade (infliximab) and biosimilars, file a written appeal within 180 days. The appeal must cite the insurer's clinical policy, include a letter of medical necessity from the prescriber, and document each criterion the policy requires. The most common winning evidence is documented prior therapy history and a specialist letter.

Typical PA criteria

  • Approved indication with ICD-10
  • Prior DMARD or conventional therapy trial
  • Specialist prescriber
  • TB/HBV screening
  • Infusion site of care per plan

Why your PA was denied

  • Brand Remicade not covered; biosimilar (Inflectra, Avsola, Renflexis) required
  • Site of care denial (hospital outpatient vs. home/office infusion)
  • DMARD trial not documented
  • Screening absent

Evidence that overturns the denial

  • ✓Prior DMARD trial documentation
  • ✓Baseline disease activity (DAS28, HBI, Mayo)
  • ✓Screening labs
  • ✓Site-of-care justification if hospital-based required

Biosimilars (Inflectra, Avsola, Renflexis) are typically preferred; site-of-care denials often force home or office infusion instead of hospital outpatient.

Draft a Remicade (infliximab) and biosimilars appeal letter

Free analysis identifies the cited policy and missing evidence. Then a finished letter that maps your chart to the criteria.

Draft my appeal letter

FAQ

Why was my Remicade (infliximab) and biosimilars prior authorization denied?+

The most common reasons are: Brand Remicade not covered; biosimilar (Inflectra, Avsola, Renflexis) required; Site of care denial (hospital outpatient vs. home/office infusion); DMARD trial not documented. Your denial letter names the specific criteria you did not meet.

How do I appeal a Remicade (infliximab) and biosimilars denial?+

File a written appeal within 180 days that cites the insurer's clinical policy, includes a letter of medical necessity from the prescriber, and documents the criteria the insurer requires.

What evidence overturns a Remicade (infliximab) and biosimilars denial?+

Prior DMARD trial documentation; Baseline disease activity (DAS28, HBI, Mayo); Screening labs.

What if the plan excludes Remicade (infliximab) and biosimilars entirely?+

Plan exclusions are different from medical-necessity denials. Check the Summary Plan Description. If the drug is fully excluded, an appeal will not overturn it; you may need a formulary exception or manufacturer assistance program.

Other drugs

Keep reading

Not legal or medical advice. This page is a self-help resource. You make your own decisions. Strip personal identifiers (name, date of birth, address, member ID) from any document before uploading or sharing. The information here summarizes commonly-published payer policies and federal rules; confirm against your specific plan document and the current denial letter before acting.